{"session": {"id": "a6d1a348-19e1-4018-9920-5cc3aa7a080c", "question": "what is AD?", "answer": "Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline, memory loss, and dementia. It is primarily associated with the accumulation of amyloid-beta (A\u03b2) peptides in the brain, which trigger a cascade of neurodegenerative processes, including synaptic dysfunction, neuronal damage, and brain atrophy (Golde2011 chunk 1; Golde2011 chunk 2; Busche2014 chunk 4). A\u03b2 disrupts synaptic glutamate uptake, induces synaptic depression, and destabilizes neural network activity, leading to aberrant excitatory and inhibitory responses, epileptiform activity, and cognitive impairments (Busche2014 chunk 3; Busche2014 chunk 4). \n\nThe disease progresses through a long prodromal phase, during which A\u03b2 aggregates accumulate over 10\u201315 years before clinical symptoms emerge. Biomarker studies show changes such as reduced cerebrospinal fluid (CSF) A\u03b242, increased tau protein levels, and brain atrophy (Golde2011 chunk 2). Microglial dysfunction, including hyper-reactivity and impaired protective functions, also contributes to neuroinflammation and neurodegeneration in AD (Microglial2025 chunk 1). \n\nAD is strongly age-related, with risk doubling approximately every five years after age 65. By age 85, the likelihood of AD-related dementia ranges from 25% to over 40% (Golde2011 chunk 1). Current therapies provide minimal symptomatic relief and do not significantly alter disease progression (Golde2011 chunk 1).", "answer_reasoning": null, "has_successful_answer": true, "context": "Golde2011 chunk 1: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive impairment and dementia. It is primarily associated with the accumulation of amyloid beta-protein (A\u03b2) aggregates in the brain, which trigger a complex neurodegenerative cascade. The disease is strongly age-related, with risk doubling approximately every five years after age 65. By age 85, the likelihood of having AD-related dementia ranges from 25% to over 40%. The prevalence of AD is expected to increase significantly due to rising life expectancy, with over 100 million individuals predicted to have AD by 2050. Current therapies provide minimal symptomatic relief and do not significantly alter disease progression.\nFrom Golde, Todd E., et al. \"Anti-A\u03b2 Therapeutics in Alzheimer\u2019s Disease: The Need for a Paradigm Shift.\" *Neuron*, vol. 69, no. 2, 2011, pp. 203\u2013213. *ScienceDirect*, https://doi.org/10.1016/j.neuron.2011.01.002. Accessed 30 Oct. 2025.\n\nBusche2014 chunk 3: Alzheimer's disease is a neurodegenerative disorder characterized by cognitive decline, synaptic dysfunction, and neural network instability. Pathologically elevated levels of amyloid-beta (A\u03b2) play a central role in its progression by disrupting synaptic glutamate uptake, leading to synaptic depression and long-term depression (LTD). A\u03b2 also destabilizes neural network activity, causing aberrant excitatory and inhibitory responses, epileptiform activity, and compensatory mechanisms in learning and memory circuits. These disruptions contribute to cognitive impairments. Radiological studies show hypometabolism and atrophy in brain regions, particularly the default network, and functional MRI studies reveal abnormal increases in network activity during memory tasks. Seizures and epileptiform activity are more common in Alzheimer's patients, especially in early-onset cases.\nFrom Busche, Marc A., and Bradley T. Hyman. \"Amyloid-\u03b2 Induced Neuronal Dysfunction in Alzheimer\u2019s Disease: From Synapses toward Neural Networks.\" *Nature Neuroscience*, vol. 17, no. 6, 2014, pp. 683\u2013690. *Nature*, https://doi.org/10.1038/nn.3697. Accessed 30 Oct. 2025.\n\nBusche2014 chunk 4: Alzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive decline and memory loss. It is associated with the accumulation of amyloid-beta (A\u03b2) peptides, which disrupt neuronal and synaptic function. A\u03b2 can cause network instability, synaptic depression, and aberrant synchronization, potentially leading to epileptiform activity. GABAergic dysfunction, astrocytic hyperactivity, and microglial inflammation also contribute to network dysfunction. A\u03b2 oligomers, rather than plaques, are thought to play a more critical role in synaptic and cognitive impairments. Other factors, such as tau protein, apoE4, and oxidative stress, may also contribute to the disease's pathogenesis. Research continues to explore these mechanisms and potential therapeutic targets.\nFrom Busche, Marc A., and Bradley T. Hyman. \"Amyloid-\u03b2 Induced Neuronal Dysfunction in Alzheimer\u2019s Disease: From Synapses toward Neural Networks.\" *Nature Neuroscience*, vol. 17, no. 6, 2014, pp. 683\u2013690. *Nature*, https://doi.org/10.1038/nn.3697. Accessed 30 Oct. 2025.\n\nGolde2011 chunk 2: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the accumulation of misfolded protein aggregates, particularly amyloid-beta (A\u03b2) peptides, in the brain. This accumulation triggers a degenerative cascade leading to neuronal damage, synaptic loss, and eventual brain failure. AD progresses through a long prodromal phase, during which A\u03b2 aggregates accumulate over 10\u201315 years before clinical symptoms like cognitive impairment and dementia become apparent. Biomarker studies reveal changes such as low cerebrospinal fluid (CSF) A\u03b242, increased tau protein levels, and brain atrophy. The disease is hypothesized to follow a cascade where A\u03b2 accumulation initiates neurodegeneration, though the effectiveness of anti-A\u03b2 therapies remains uncertain.\nFrom Golde, Todd E., et al. \"Anti-A\u03b2 Therapeutics in Alzheimer\u2019s Disease: The Need for a Paradigm Shift.\" *Neuron*, vol. 69, no. 2, 2011, pp. 203\u2013213. *ScienceDirect*, https://doi.org/10.1016/j.neuron.2011.01.002. Accessed 30 Oct. 2025.\n\nMicroglial2025 chunk 1: Alzheimer's disease (AD) is a neurodegenerative condition primarily affecting the aged brain, characterized by neuroinflammatory events involving glial cells, particularly microglia. It was first described by Alois Alzheimer in 1907, who noted inflammatory changes in the brain. AD is associated with aging and involves dysfunction in microglial cells, which are the immune cells of the central nervous system. These cells undergo morphological and molecular changes with age, and their protective functions may deteriorate or become hyper-reactive, contributing to neurodegeneration. Genetic factors, systemic inflammation, and lifestyle factors like obesity can exacerbate these changes, pushing aging microglia toward an AD state.\nFrom \"Microglial Dysfunction in Brain Aging and Alzheimer\u2019s Disease.\" *Journal of Neuroscience Research*, vol. XX, no. XX, 2025, pp. XX-XX. Accessed [insert date of access], 2025.\n\nValid Keys: Golde2011 chunk 1, Busche2014 chunk 3, Busche2014 chunk 4, Golde2011 chunk 2, Microglial2025 chunk 1", "contexts": [{"context": "Alzheimer's disease is a neurodegenerative disorder characterized by cognitive decline, synaptic dysfunction, and neural network instability. Pathologically elevated levels of amyloid-beta (A\u03b2) play a central role in its progression by disrupting synaptic glutamate uptake, leading to synaptic depression and long-term depression (LTD). A\u03b2 also destabilizes neural network activity, causing aberrant excitatory and inhibitory responses, epileptiform activity, and compensatory mechanisms in learning and memory circuits. These disruptions contribute to cognitive impairments. Radiological studies show hypometabolism and atrophy in brain regions, particularly the default network, and functional MRI studies reveal abnormal increases in network activity during memory tasks. Seizures and epileptiform activity are more common in Alzheimer's patients, especially in early-onset cases.", "question": "What is Alzheimer's disease?", "text": {"embedding": null, "text": "", "name": "Busche2014 chunk 3", "doc": {"embedding": null, "docname": "Busche2014", "dockey": "4840b09e20c5be96da7757dfbce3ce8f", "citation": "Busche, Marc A., and Bradley T. Hyman. \"Amyloid-\u03b2 Induced Neuronal Dysfunction in Alzheimer\u2019s Disease: From Synapses toward Neural Networks.\" *Nature Neuroscience*, vol. 17, no. 6, 2014, pp. 683\u2013690. *Nature*, https://doi.org/10.1038/nn.3697. Accessed 30 Oct. 2025.", "fields_to_overwrite_from_metadata": ["doc_id", "key", "dockey", "docname", "citation"], "formatted_citation": "Busche, Marc A., and Bradley T. Hyman. \"Amyloid-\u03b2 Induced Neuronal Dysfunction in Alzheimer\u2019s Disease: From Synapses toward Neural Networks.\" *Nature Neuroscience*, vol. 17, no. 6, 2014, pp. 683\u2013690. *Nature*, https://doi.org/10.1038/nn.3697. Accessed 30 Oct. 2025."}}, "score": 9}, {"context": "Alzheimer's disease (AD) is a neurodegenerative condition primarily affecting the aged brain, characterized by neuroinflammatory events involving glial cells, particularly microglia. It was first described by Alois Alzheimer in 1907, who noted inflammatory changes in the brain. AD is associated with aging and involves dysfunction in microglial cells, which are the immune cells of the central nervous system. These cells undergo morphological and molecular changes with age, and their protective functions may deteriorate or become hyper-reactive, contributing to neurodegeneration. Genetic factors, systemic inflammation, and lifestyle factors like obesity can exacerbate these changes, pushing aging microglia toward an AD state.", "question": "What is Alzheimer's disease?", "text": {"embedding": null, "text": "", "name": "Microglial2025 chunk 1", "doc": {"embedding": null, "docname": "Microglial2025", "dockey": "164023fe066fcfc7431aedf9fd46bdc3", "citation": "\"Microglial Dysfunction in Brain Aging and Alzheimer\u2019s Disease.\" *Journal of Neuroscience Research*, vol. XX, no. XX, 2025, pp. XX-XX. Accessed [insert date of access], 2025.", "fields_to_overwrite_from_metadata": ["doc_id", "key", "dockey", "docname", "citation"], "formatted_citation": "\"Microglial Dysfunction in Brain Aging and Alzheimer\u2019s Disease.\" *Journal of Neuroscience Research*, vol. XX, no. XX, 2025, pp. XX-XX. Accessed [insert date of access], 2025."}}, "score": 9}, {"context": "Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline, which is strongly associated with the accumulation of amyloid-beta (A\u03b2) plaques in the brain. The amyloid hypothesis suggests that A\u03b2 aggregation is a primary initiator of AD pathogenesis, leading to downstream effects such as oxidative stress, inflammation, mitochondrial dysfunction, and impaired autophagy. These processes contribute to neurodegeneration but are not unique to AD. Factors like age-related decline in A\u03b2 clearance, oxidative stress, sleep disruption, and genetic predispositions (e.g., ApoE genotype) may disturb A\u03b2 homeostasis, triggering its aggregation. Cognitive symptoms in AD typically emerge years after significant plaque deposition and tau pathology.", "question": "What is Alzheimer's disease?", "text": {"embedding": null, "text": "", "name": "Three2025 chunk 4", "doc": {"embedding": null, "docname": "Three2025", "dockey": "f4e1b9f2728e51bf73ea5a4554cfe0dd", "citation": "\"Three Dimensions of the Amyloid Hypothesis: Time, Space, and 'Wingmen.'\" *Journal of Alzheimer's Disease*, vol. XX, no. XX, 2025, pp. XX-XX. Accessed 30 Oct. 2025.", "fields_to_overwrite_from_metadata": ["doc_id", "key", "dockey", "docname", "citation"], "formatted_citation": "\"Three Dimensions of the Amyloid Hypothesis: Time, Space, and 'Wingmen.'\" *Journal of Alzheimer's Disease*, vol. XX, no. XX, 2025, pp. XX-XX. Accessed 30 Oct. 2025."}}, "score": 9}, {"context": "Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive impairment and dementia. It is primarily associated with the accumulation of amyloid beta-protein (A\u03b2) aggregates in the brain, which trigger a complex neurodegenerative cascade. The disease is strongly age-related, with risk doubling approximately every five years after age 65. By age 85, the likelihood of having AD-related dementia ranges from 25% to over 40%. The prevalence of AD is expected to increase significantly due to rising life expectancy, with over 100 million individuals predicted to have AD by 2050. Current therapies provide minimal symptomatic relief and do not significantly alter disease progression.", "question": "What is Alzheimer's disease?", "text": {"embedding": null, "text": "", "name": "Golde2011 chunk 1", "doc": {"embedding": null, "docname": "Golde2011", "dockey": "9efddf82c55f2ee710bd9fe107f543e9", "citation": "Golde, Todd E., et al. \"Anti-A\u03b2 Therapeutics in Alzheimer\u2019s Disease: The Need for a Paradigm Shift.\" *Neuron*, vol. 69, no. 2, 2011, pp. 203\u2013213. *ScienceDirect*, https://doi.org/10.1016/j.neuron.2011.01.002. Accessed 30 Oct. 2025.", "fields_to_overwrite_from_metadata": ["doc_id", "key", "dockey", "docname", "citation"], "formatted_citation": "Golde, Todd E., et al. \"Anti-A\u03b2 Therapeutics in Alzheimer\u2019s Disease: The Need for a Paradigm Shift.\" *Neuron*, vol. 69, no. 2, 2011, pp. 203\u2013213. *ScienceDirect*, https://doi.org/10.1016/j.neuron.2011.01.002. Accessed 30 Oct. 2025."}}, "score": 10}, {"context": "Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline and memory loss. Central to its pathology is the accumulation of amyloid-beta (A\u03b2) plaques and tau tangles in the brain. A\u03b2 can induce misfolding of other toxic proteins like tau, \u03b1-synuclein, and TDP-43, contributing to neurodegeneration. A\u03b2-related changes often precede tau pathology and cognitive symptoms by years, suggesting a preclinical phase. Oligomeric forms of A\u03b2, rather than plaques, may play a critical role in initiating tau pathology and neurodegeneration. Aging, along with factors like inflammation, oxidative stress, and vascular issues, exacerbates A\u03b2 toxicity and accelerates disease progression.", "question": "What is Alzheimer's disease?", "text": {"embedding": null, "text": "", "name": "Three2025 chunk 3", "doc": {"embedding": null, "docname": "Three2025", "dockey": "f4e1b9f2728e51bf73ea5a4554cfe0dd", "citation": "\"Three Dimensions of the Amyloid Hypothesis: Time, Space, and 'Wingmen.'\" *Journal of Alzheimer's Disease*, vol. XX, no. XX, 2025, pp. XX-XX. Accessed 30 Oct. 2025.", "fields_to_overwrite_from_metadata": ["doc_id", "key", "dockey", "docname", "citation"], "formatted_citation": "\"Three Dimensions of the Amyloid Hypothesis: Time, Space, and 'Wingmen.'\" *Journal of Alzheimer's Disease*, vol. XX, no. XX, 2025, pp. XX-XX. Accessed 30 Oct. 2025."}}, "score": 9}, {"context": "Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline and memory loss. The Amyloid Hypothesis suggests that amyloid-beta peptide (A\u03b2) is the primary initiator of AD pathology. Genetic evidence supports this, as mutations in genes like APP, PSEN1, and PSEN2, which are involved in A\u03b2 production, cause familial AD (fAD). A\u03b2 aggregation triggers a cascade of downstream processes, including tau aggregation, neuronal loss, and dementia. While fAD is rare, sporadic AD (sAD) is more common and influenced by genetic factors like the APOE \u03b54 allele, which exacerbates A\u03b2 aggregation. A\u03b2 is necessary but not sufficient to cause AD, acting as an early trigger in the disease process.", "question": "What is Alzheimer's disease?", "text": {"embedding": null, "text": "", "name": "Three2025 chunk 1", "doc": {"embedding": null, "docname": "Three2025", "dockey": "f4e1b9f2728e51bf73ea5a4554cfe0dd", "citation": "\"Three Dimensions of the Amyloid Hypothesis: Time, Space, and 'Wingmen.'\" *Journal of Alzheimer's Disease*, vol. XX, no. XX, 2025, pp. XX-XX. Accessed 30 Oct. 2025.", "fields_to_overwrite_from_metadata": ["doc_id", "key", "dockey", "docname", "citation"], "formatted_citation": "\"Three Dimensions of the Amyloid Hypothesis: Time, Space, and 'Wingmen.'\" *Journal of Alzheimer's Disease*, vol. XX, no. XX, 2025, pp. XX-XX. Accessed 30 Oct. 2025."}}, "score": 9}, {"context": "Alzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive decline and memory loss. It is associated with the accumulation of amyloid-beta (A\u03b2) peptides, which disrupt neuronal and synaptic function. A\u03b2 can cause network instability, synaptic depression, and aberrant synchronization, potentially leading to epileptiform activity. GABAergic dysfunction, astrocytic hyperactivity, and microglial inflammation also contribute to network dysfunction. A\u03b2 oligomers, rather than plaques, are thought to play a more critical role in synaptic and cognitive impairments. Other factors, such as tau protein, apoE4, and oxidative stress, may also contribute to the disease's pathogenesis. Research continues to explore these mechanisms and potential therapeutic targets.", "question": "What is Alzheimer's disease?", "text": {"embedding": null, "text": "", "name": "Busche2014 chunk 4", "doc": {"embedding": null, "docname": "Busche2014", "dockey": "4840b09e20c5be96da7757dfbce3ce8f", "citation": "Busche, Marc A., and Bradley T. Hyman. \"Amyloid-\u03b2 Induced Neuronal Dysfunction in Alzheimer\u2019s Disease: From Synapses toward Neural Networks.\" *Nature Neuroscience*, vol. 17, no. 6, 2014, pp. 683\u2013690. *Nature*, https://doi.org/10.1038/nn.3697. Accessed 30 Oct. 2025.", "fields_to_overwrite_from_metadata": ["doc_id", "key", "dockey", "docname", "citation"], "formatted_citation": "Busche, Marc A., and Bradley T. Hyman. \"Amyloid-\u03b2 Induced Neuronal Dysfunction in Alzheimer\u2019s Disease: From Synapses toward Neural Networks.\" *Nature Neuroscience*, vol. 17, no. 6, 2014, pp. 683\u2013690. *Nature*, https://doi.org/10.1038/nn.3697. Accessed 30 Oct. 2025."}}, "score": 9}, {"context": "Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the accumulation of misfolded protein aggregates, particularly amyloid-beta (A\u03b2) peptides, in the brain. This accumulation triggers a degenerative cascade leading to neuronal damage, synaptic loss, and eventual brain failure. AD progresses through a long prodromal phase, during which A\u03b2 aggregates accumulate over 10\u201315 years before clinical symptoms like cognitive impairment and dementia become apparent. Biomarker studies reveal changes such as low cerebrospinal fluid (CSF) A\u03b242, increased tau protein levels, and brain atrophy. The disease is hypothesized to follow a cascade where A\u03b2 accumulation initiates neurodegeneration, though the effectiveness of anti-A\u03b2 therapies remains uncertain.", "question": "What is Alzheimer's disease?", "text": {"embedding": null, "text": "", "name": "Golde2011 chunk 2", "doc": {"embedding": null, "docname": "Golde2011", "dockey": "9efddf82c55f2ee710bd9fe107f543e9", "citation": "Golde, Todd E., et al. \"Anti-A\u03b2 Therapeutics in Alzheimer\u2019s Disease: The Need for a Paradigm Shift.\" *Neuron*, vol. 69, no. 2, 2011, pp. 203\u2013213. *ScienceDirect*, https://doi.org/10.1016/j.neuron.2011.01.002. Accessed 30 Oct. 2025.", "fields_to_overwrite_from_metadata": ["doc_id", "key", "dockey", "docname", "citation"], "formatted_citation": "Golde, Todd E., et al. \"Anti-A\u03b2 Therapeutics in Alzheimer\u2019s Disease: The Need for a Paradigm Shift.\" *Neuron*, vol. 69, no. 2, 2011, pp. 203\u2013213. *ScienceDirect*, https://doi.org/10.1016/j.neuron.2011.01.002. Accessed 30 Oct. 2025."}}, "score": 9}, {"context": "Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline and memory loss. The excerpt highlights the role of microglia, the brain's immune cells, in the disease. Genetic studies have identified associations between AD and genes like TREM2, TYROBP, CLU, and CR1, which are involved in immune and phagocytic functions. Microglial dysfunction, including impaired phagocytosis and increased inflammation, is implicated in AD pathology. Aging-related changes in immune components, such as increased TREM2 expression, may represent compensatory mechanisms but often fail to prevent neurodegeneration. These findings suggest a complex interplay between aging, immune dysregulation, and AD development.", "question": "What is Alzheimer's disease?", "text": {"embedding": null, "text": "", "name": "Microglial2025 chunk 2", "doc": {"embedding": null, "docname": "Microglial2025", "dockey": "164023fe066fcfc7431aedf9fd46bdc3", "citation": "\"Microglial Dysfunction in Brain Aging and Alzheimer\u2019s Disease.\" *Journal of Neuroscience Research*, vol. XX, no. XX, 2025, pp. XX-XX. Accessed [insert date of access], 2025.", "fields_to_overwrite_from_metadata": ["doc_id", "key", "dockey", "docname", "citation"], "formatted_citation": "\"Microglial Dysfunction in Brain Aging and Alzheimer\u2019s Disease.\" *Journal of Neuroscience Research*, vol. XX, no. XX, 2025, pp. XX-XX. Accessed [insert date of access], 2025."}}, "score": 8}, {"context": "Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the accumulation of amyloid-beta (A\u03b2) plaques and tau protein tangles in the brain. The amyloid hypothesis suggests that A\u03b2 aggregation is a primary driver of the disease, triggering downstream tau pathology and neuronal degeneration. A\u03b2 plaques are found in regions like the precuneus and frontal lobes, while tau pathology and neuronal loss occur in areas like the entorhinal cortex and hippocampus. Genetic factors, such as ApoE4 and mutations in the APP gene, influence A\u03b2 aggregation and AD risk. Preclinical studies show A\u03b2 can induce tau pathology and neurodegeneration, supporting its role in disease progression.", "question": "What is Alzheimer's disease?", "text": {"embedding": null, "text": "", "name": "Three2025 chunk 2", "doc": {"embedding": null, "docname": "Three2025", "dockey": "f4e1b9f2728e51bf73ea5a4554cfe0dd", "citation": "\"Three Dimensions of the Amyloid Hypothesis: Time, Space, and 'Wingmen.'\" *Journal of Alzheimer's Disease*, vol. XX, no. XX, 2025, pp. XX-XX. Accessed 30 Oct. 2025.", "fields_to_overwrite_from_metadata": ["doc_id", "key", "dockey", "docname", "citation"], "formatted_citation": "\"Three Dimensions of the Amyloid Hypothesis: Time, Space, and 'Wingmen.'\" *Journal of Alzheimer's Disease*, vol. XX, no. XX, 2025, pp. XX-XX. Accessed 30 Oct. 2025."}}, "score": 9}], "references": "1. (Golde2011 chunk 1): Golde, Todd E., et al. \"Anti-A\u03b2 Therapeutics in Alzheimer\u2019s Disease: The Need for a Paradigm Shift.\" *Neuron*, vol. 69, no. 2, 2011, pp. 203\u2013213. *ScienceDirect*, https://doi.org/10.1016/j.neuron.2011.01.002. Accessed 30 Oct. 2025.\n\n2. (Busche2014 chunk 3): Busche, Marc A., and Bradley T. Hyman. \"Amyloid-\u03b2 Induced Neuronal Dysfunction in Alzheimer\u2019s Disease: From Synapses toward Neural Networks.\" *Nature Neuroscience*, vol. 17, no. 6, 2014, pp. 683\u2013690. *Nature*, https://doi.org/10.1038/nn.3697. Accessed 30 Oct. 2025.\n\n3. (Busche2014 chunk 4): Busche, Marc A., and Bradley T. Hyman. \"Amyloid-\u03b2 Induced Neuronal Dysfunction in Alzheimer\u2019s Disease: From Synapses toward Neural Networks.\" *Nature Neuroscience*, vol. 17, no. 6, 2014, pp. 683\u2013690. *Nature*, https://doi.org/10.1038/nn.3697. Accessed 30 Oct. 2025.\n\n4. (Golde2011 chunk 2): Golde, Todd E., et al. \"Anti-A\u03b2 Therapeutics in Alzheimer\u2019s Disease: The Need for a Paradigm Shift.\" *Neuron*, vol. 69, no. 2, 2011, pp. 203\u2013213. *ScienceDirect*, https://doi.org/10.1016/j.neuron.2011.01.002. Accessed 30 Oct. 2025.\n\n5. (Microglial2025 chunk 1): \"Microglial Dysfunction in Brain Aging and Alzheimer\u2019s Disease.\" *Journal of Neuroscience Research*, vol. XX, no. XX, 2025, pp. XX-XX. Accessed [insert date of access], 2025.", "formatted_answer": "Question: what is AD?\n\nAlzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline, memory loss, and dementia. It is primarily associated with the accumulation of amyloid-beta (A\u03b2) peptides in the brain, which trigger a cascade of neurodegenerative processes, including synaptic dysfunction, neuronal damage, and brain atrophy (Golde2011 chunk 1; Golde2011 chunk 2; Busche2014 chunk 4). A\u03b2 disrupts synaptic glutamate uptake, induces synaptic depression, and destabilizes neural network activity, leading to aberrant excitatory and inhibitory responses, epileptiform activity, and cognitive impairments (Busche2014 chunk 3; Busche2014 chunk 4). \n\nThe disease progresses through a long prodromal phase, during which A\u03b2 aggregates accumulate over 10\u201315 years before clinical symptoms emerge. Biomarker studies show changes such as reduced cerebrospinal fluid (CSF) A\u03b242, increased tau protein levels, and brain atrophy (Golde2011 chunk 2). Microglial dysfunction, including hyper-reactivity and impaired protective functions, also contributes to neuroinflammation and neurodegeneration in AD (Microglial2025 chunk 1). \n\nAD is strongly age-related, with risk doubling approximately every five years after age 65. By age 85, the likelihood of AD-related dementia ranges from 25% to over 40% (Golde2011 chunk 1). Current therapies provide minimal symptomatic relief and do not significantly alter disease progression (Golde2011 chunk 1).\n\nReferences\n\n1. (Golde2011 chunk 1): Golde, Todd E., et al. \"Anti-A\u03b2 Therapeutics in Alzheimer\u2019s Disease: The Need for a Paradigm Shift.\" *Neuron*, vol. 69, no. 2, 2011, pp. 203\u2013213. *ScienceDirect*, https://doi.org/10.1016/j.neuron.2011.01.002. Accessed 30 Oct. 2025.\n\n2. (Busche2014 chunk 3): Busche, Marc A., and Bradley T. Hyman. \"Amyloid-\u03b2 Induced Neuronal Dysfunction in Alzheimer\u2019s Disease: From Synapses toward Neural Networks.\" *Nature Neuroscience*, vol. 17, no. 6, 2014, pp. 683\u2013690. *Nature*, https://doi.org/10.1038/nn.3697. Accessed 30 Oct. 2025.\n\n3. (Busche2014 chunk 4): Busche, Marc A., and Bradley T. Hyman. \"Amyloid-\u03b2 Induced Neuronal Dysfunction in Alzheimer\u2019s Disease: From Synapses toward Neural Networks.\" *Nature Neuroscience*, vol. 17, no. 6, 2014, pp. 683\u2013690. *Nature*, https://doi.org/10.1038/nn.3697. Accessed 30 Oct. 2025.\n\n4. (Golde2011 chunk 2): Golde, Todd E., et al. \"Anti-A\u03b2 Therapeutics in Alzheimer\u2019s Disease: The Need for a Paradigm Shift.\" *Neuron*, vol. 69, no. 2, 2011, pp. 203\u2013213. *ScienceDirect*, https://doi.org/10.1016/j.neuron.2011.01.002. Accessed 30 Oct. 2025.\n\n5. (Microglial2025 chunk 1): \"Microglial Dysfunction in Brain Aging and Alzheimer\u2019s Disease.\" *Journal of Neuroscience Research*, vol. XX, no. XX, 2025, pp. XX-XX. Accessed [insert date of access], 2025.\n", "graded_answer": null, "cost": 0.07452500000000001, "token_counts": {"gpt-4o-2024-11-20": [21650, 2040]}, "config_md5": "f8536e29e2dd2b396e3bba5533814e40", "tool_history": [["paper_search"], ["gather_evidence"], ["gen_answer"], ["complete"]], "used_contexts": ["Golde2011 chunk 2", "Microglial2025 chunk 1", "Busche2014 chunk 3", "Golde2011 chunk 1", "Busche2014 chunk 4"]}, "bibtex": null, "status": "success", "timing_info": null, "duration": 0.0, "stats": null}